In a recent study, researchers from Shanghai Jiao Tong University in China investigated the epigenetic program responsible for cartilage injury induced by aberrant mechanical force, with the final aim of exploring a potential epigenetic-based therapy approach for osteoarthritis.
A new method has been devised to produce generic chimeric antigen receptor (CAR) T cells at scale by directing induced pluripotent stem cells (iPSCs) to differentiate into mature T cells in vitro. The generic T cells can then be engineered to express a range of different chimeric antigen receptors.
To explore the role of histone deacetylase 11 (HDAC11) in Alzheimer's disease, Massachusetts General Hospital researchers generated selective, brain-penetrating HDAC11 inhibitors.
Innovation Pharmaceuticals' brilacidin, a defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus.
AbbVie has patented cystic fibrosis transmembrane conductance regulator (CFTR) (deltaF508 mutant) correctors reported to be useful for the treatment of cystic fibrosis.
Thryv Therapeutics has presented new pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives acting as serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors reported to be useful for the treatment of cancer, cardiovascular disorders, Lafora disease and Parkinson's disease.
Pfizer has patented isolated engineered immune cells expressing chimeric antigen receptors (CARs) comprising an epidermal growth factor receptor variant 3 (EGFRvIII) binding domain, a transmembrane domain and an intracellular signaling domain claimed to be potentially useful for the treatment of cancer.
Researchers developed three novel non-small cell lung cancer (NSCLC) patient-derived echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion cell lines, including CUTO8 (variant 1), 9 (variant 1) and 29 (variant 3), as well as a fourth ALK-positive cell line, YU1077 (EML4-ALK variant 3).
RSS